The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Beta Cell Centric Approach in the Management of Diabetes


Affiliations
1 President-Medical & Regulatory Affairs, Dept. of Scientific;, India
2 Deputy General Manager-Medical, Dept. of Scientific, India
3 Assistant General Manager-Medical, Dept. of Scientific;, India
4 Senior Executive-Scientific, Dept. of Scientific, Aristo Pharmaceuticals Private Limited,, India
     

   Subscribe/Renew Journal


Type 2 Diabetes (T2DM) is a complex, progressive, chronic metabolic disorder that is mainly characterized by hyperglycemia. The decline in β-cell function and insulin resistance still remains the major pathophysiological mechanisms of disease progression. By the time T2DM is diagnosed, the β-cell function is already lost halfway, which further declines each year thereafter. The majority of the currently present therapy focuses more on achieving glycemic targets without dealing with the deteriorating β-cell function. Various classes of drugs in managing T2DM aids in improving β-cell function and proliferation including newer agents like Glucagon Like Polypeptide-1 Receptor Agonist (GLP-1RA), Sodium-Glucose Co-Transporter-2 inhibitors (SGLT2i) and Dipeptidyl-Peptidase 4 inhibitors (DPP4i). This review highlights the fate of β-cell function during T2DM progression and the therapeutic approach for β-cell preservation with special emphasis on DPP4i.

Keywords

Type 2 Diabetes (T2DM), β-cell preservation, Dipeptidyl-Peptidase 4 inhibitors (DPP4i), Sitagliptin.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Saisho Y. An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opin Pharmacother. 2020;21(13):1565-78. DOI: 10.1080/14656566.2020.1776262. PMID: 32521177

  • Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;27;4:37. DOI: 10.3389/fendo. 2013.00037. PMID: 23542897; PMCID: PMC3608918.

  • Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad Med. 2020;132(8):676-86. DOI: 10.1080/00325481.2020.1771047. Epub 2020 Jun 16. PMID: 32543261.

  • DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96(8):2354-66. DOI: 10.1210/jc.2011-0246. Epub 2011 Jun 22. PMID: 21697254.

  • Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012;150(6):1223-34. DOI: 10.1016/j.cell.2012.07.029. PMID: 22980982; PMCID: PMC3445031.

  • Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489-512. DOI: 10.2165/11203790-000000000-00000. PMID: 20205490.

  • Jung KY, Kim KM, Lim S. Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. Diabetes Metab J. 2014;38(6):426-36. DOI: 10.4093/ dmj.2014.38.6.426. PMID: 25541605; PMCID: PMC4273028.

  • Marchetti P, Suleiman M, De Luca C, Baronti W, Bosi E, Tesi M, Marselli L. A direct look at the dysfunction and pathology of the β cells in human type 2 diabetes. Semin Cell Dev Biol. 2020;103:83-93. DOI: 10.1016/j.semcdb.2020.04.005. Epub 2020 May 13. PMID: 32417220.

  • Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab. 2008;10 Suppl 4(0 4):23-31. DOI: 10.1111/j.1463-1326.2008.00939.x. PMID: 18834430; PMCID: PMC3375862.

  • Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187- 218. DOI: 10.1210/10.1210/er.2006-0038. Epub 2007 Mar 12. PMID: 17353295.

  • Swisa A, Glaser B, Dor Y. Metabolic Stress and Compromised Identity of Pancreatic Beta Cells. Front Genet. 2017;8:21. DOI: 10.3389/fgene.2017.00021. PMID: 28270834; PMCID: PMC5318414.

  • Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep. 2017;7:44865. DOI: 10.1038/srep44865. PMID: 28322294; PMCID: PMC5359588.

  • Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017;77(2):209-24. DOI: 10.1007/s40265-016-0686-9. PMID: 28078647.

  • Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106-16. DOI: 10.1016/j.diabres.2008.10.009. Epub 2008 Dec 20. PMID: 19097665.

  • Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-7. DOI: 10.2337/dc06-0703. PMID: 17130196.

  • Le TD, Nguyen NTP, Nguyen ST, Tran HTT, Nguyen LTH, Duong HH, Nguyen HM, Do BN. Sitagliptin Increases Beta- Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020 Jun;13:2119 127. DOI: 10.2147/DMSO.S255071. PMID: 32606870; PMCID: PMC7310979.

  • Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442-51. DOI: 10.1111/j.1463- 1326.2010.01204.x. PMID: 20415693.

  • Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-43. DOI: 10.2337/dc06-0706. PMID: 17130197.

  • Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-206. DOI: 10.1152/ajpendo.00545.2003. PMID: 15271645.


Abstract Views: 186

PDF Views: 0




  • Beta Cell Centric Approach in the Management of Diabetes

Abstract Views: 186  |  PDF Views: 0

Authors

Dr. Manish Maladkar
President-Medical & Regulatory Affairs, Dept. of Scientific;, India
Dr. Shrikant Patil
Deputy General Manager-Medical, Dept. of Scientific, India
Dr. Ashok Yadav
Assistant General Manager-Medical, Dept. of Scientific;, India
Charul Lautre
Senior Executive-Scientific, Dept. of Scientific, Aristo Pharmaceuticals Private Limited,, India

Abstract


Type 2 Diabetes (T2DM) is a complex, progressive, chronic metabolic disorder that is mainly characterized by hyperglycemia. The decline in β-cell function and insulin resistance still remains the major pathophysiological mechanisms of disease progression. By the time T2DM is diagnosed, the β-cell function is already lost halfway, which further declines each year thereafter. The majority of the currently present therapy focuses more on achieving glycemic targets without dealing with the deteriorating β-cell function. Various classes of drugs in managing T2DM aids in improving β-cell function and proliferation including newer agents like Glucagon Like Polypeptide-1 Receptor Agonist (GLP-1RA), Sodium-Glucose Co-Transporter-2 inhibitors (SGLT2i) and Dipeptidyl-Peptidase 4 inhibitors (DPP4i). This review highlights the fate of β-cell function during T2DM progression and the therapeutic approach for β-cell preservation with special emphasis on DPP4i.

Keywords


Type 2 Diabetes (T2DM), β-cell preservation, Dipeptidyl-Peptidase 4 inhibitors (DPP4i), Sitagliptin.

References